Joy Maulik, MSN, FNP-C, discusses why he built the MyUrova app and how men with prostate, bladder, kidney or testicular cancer can prepare for visits, understand their risk and set expectations for life after treatment.
|Articles|December 16, 2021
The Promise of Liquid Biopsy Tests for Detecting Cancer Earlier
Learn more about the use of liquid biopsies in cancer care.
Advertisement
Could a simple blood test let doctors find cancer sooner than current approaches? An exciting new test called a liquid biopsy looks for cancer by detecting DNA from a tumor in the blood called circulating tumor DNA or ctDNA. These tests are used currently to monitor response to cancer treatment and to choose the best treatment options for metastatic cancer. Now, several companies are offering this type of blood test to detect multiple cancers at their earliest stages but these tests may not detect cancer early enough to improve healthcare. Read more to understand FORCE’s review of the use of liquid biopsies in cancer care.
Advertisement
Related to this article
Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.
Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution about spacing out immunotherapy doses.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Testicular cancer survivor Brian Sluga shares how faith, journaling and new goals, like training for marathons, helped him live a better life after cancer.
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.
Median survival, hazard ratio, progression-free survival: a plain-language guide to the terms in cancer trial news, so you can tell what a result means for you and what to ask your care team.
Advertisement
Advertisement